Open-Label Study of AG10 in Patients With Cardiomyopathy
Status:
Active, not recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This prospective, multicenter open-label study will evaluate the long-term safety,
tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Eidos Therapeutics Eidos Therapeutics, a BridgeBio company